October 24, 2016 6:36 PM ET


Company Overview of AdvanDx, Inc.

Company Overview

AdvanDx, Inc., a biotech company, provides molecular diagnostic tests for the identification of pathogens causing critical infections in hospitalized patients. The company specializes in the molecular testing of positive blood cultures that enable clinical microbiology laboratories to report pathogen identification results earlier than with conventional testing methods. It offers QuickFISH (Fluorescence In Situ Hybridization) and PNA FISH tests for the identification of bacteria and yeast directly from positive blood cultures; XpressFISH, a platform that allows for the detection of resistance markers from positive blood cultures; and PNA Probes for ribosomal RNA sequences found in bacteria a...

400 TradeCenter

Woburn, MA 01801

United States

Founded in 2002





Key Executives for AdvanDx, Inc.

Chief Executive Officer and Director
Age: 64
Founder, Vice President of Research & Development and Director
Chief Technology Officer
Global Marketing Director
Compensation as of Fiscal Year 2016.

AdvanDx, Inc. Key Developments

OpGen, Inc., AdvanDx, Inc. - M&A Call

To discuss recent developments

AdvanDx, Inc. Receives FDA 510(K) Clearance for mecA XpressFISH

AdvanDx, Inc. announced that it has received U.S. Food and Drug Administration 510(k) clearance for its new mecA XpressFISH(TM) assay for the detection of methicillin-resistant and methicillin-susceptible Staphylococcus aureus (MRSA & MSSA) direct from blood culture samples. This phenotypic mRNA-targeting approach makes mecA XpressFISH unique in its mechanism of MRSA identification. mecA XpressFISH also provides results hours or days sooner than conventional laboratory methods which often require 48-72 hours. Drug resistance in MRSA is commonly conferred through expression of the bacterial mecA gene. mecA XpressFISH is a qualitative fluorescence in situ hybridization (FISH) assay that utilizes peptide nucleic acid (PNA) probes to bind and detect mecA messenger RNA (mRNA) sequences in blood cultures from patients infected with Staphylococcus aureus. Positive detection requires that the cells contain a functioning mecA gene.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact AdvanDx, Inc., please visit www.advandx.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.